The high frequency of genomic alterations in lymphomas affecting genes coding for proteins involved in the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway [1,2] highlights the importance of this signaling cascade as a therapeutic target. The gene discussed is MTOR; the disease is lymphoma.